Thursday, October 8, 2015
INC Research Holdings, a global phase I to IV CRO, has been certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in phase I clinical development. INC’s use of iCardiac Early Precision QT may help customers reduce costs, and increase the accuracy, reliability and speed of cardiac safety testing in clinical research.
The results of two recent studies suggest that the dispersion of clinical trials is not nearly as global as commonly believed.
Global CRO INC Research is a major sponsor and participant in the Society for Clinical Research Sites (SCRS) Asia/Pacific Site Solutions Summit set for July 30-31 in Melbourne, Australia. As part of INC’s sponsorship of the Asia/Pacific summit, the company is awarding SCRS membership scholarships to all attending sites that currently are not society members.
The Society for Clinical Research Sites (SCRS), a global trade organization representing the interests of clinical research sites, has announced an invigorated, solution-driven program for the 10th Annual Global Site Solutions Summit. The Summit will be Oct. 8-11, in Amelia Island, Fla. The annual meeting, which attracts investigators, site executives and industry executives from around the globe, is inclusive of interactive sessions, knowledge and best practice sharing, and networking opportunities, centered around the collaboration-focused theme “Better Together.”
The Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites, has announced a program for the 2015 Asia-Pac Site Solutions Summit. The Asia-Pac Site Solutions Summit will be July 30-31, 2015 in Melbourne, Australia. The Summit is open to clinical research investigators, site executives and industry stakeholders.
Global CRO INC Research has launched a Site Advocacy Group (SAG) devoted to the scientific and operational aspects of clinical research. The SAG initially will focus on central nervous system (CNS) protocols—recognized as among the more complex therapeutic areas in clinical research—targeting psychiatry studies including, but not limited to, those in schizophrenia, attention-deficit/hyperactivity disorder (ADHD), depression and bipolar disorder.
Global CRO INC Research Holdings has announced a strategic collaboration with DrugDev to drive increased efficiencies in clinical trials through enhanced access to and management of critical investigator and site data. INC Research becomes the first CRO to complete integration with and implementation of DrugDev’s SiteCloud platform, the same technology used by TransCelerate’s Investigator Registry (launching later this year) and the Investigator Databank, to facilitate more efficient feasibility, site selection and study start-up processes.